Indirect Comparison of SGLT2 Inhibitors in Patients with Established Heart Failure: Evidence Based on Bayesian Methods
ESC Heart Failure · 2023
DOI: 10.1002/ehf2.14297 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Hai-Bin Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China, 510317. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Heart Failure. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
Head-to-head comparisons among SGLT2 inhibitors treatments in established heart failure remain absent. We conducted a systematic review of dedicated heart failure trials to assess indirectly the composite outcomes and individual clinical endpoints among SGLT2 inhibitor treatments. Methods and results We systematically reviewed randomized controlled trials comparing SGLT2 inhibitors versus placebo in patients with established heart failure. A Bayesian approach to network meta-analysis was applied. Five trials including four treatment strategies were included in this study. The composite of cardiovascular death or hospitalization for heart failure showed no significant difference in the comparison between dapagliflozin and empagliflozin (OR 1.00, 95% CI 0.66–1.55), dapagliflozin and sotagliflozin (OR 1.54, 95% CI 0.91–2.65), and empagliflozin and sotagliflozin (OR 1.53, 95% CI 0.90–2.69). All-cause mortality showed no significant difference in the comparison between dapagliflozin and empagliflozin (OR 0.92, 95% CI 0.711–1.18), dapagliflozin and sotagliflozin (OR 1.05, 95% CI 0.68–1.59), and empagliflozin and sotagliflozin (OR 1.14, 95% CI 0.74–1.73). Cardiovascular death showed no significant difference in the comparison between dapagliflozin and empagliflozin (OR 0.94, 95% CI 0.71–1.23), dapagliflozin and sotagliflozin (OR 0.96, 95% CI 0.61–1.55), and empagliflozin and sotagliflozin (OR 1.03, 95% CI 0.64–1.66). Hospitalization for heart failure showed no significant difference in the comparison between dapagliflozin and empagliflozin (OR 1.13, 95% CI 0.64–1.97), dapagliflozin and sotagliflozin (OR 1.56, 95% CI 0.74–3.15), and empagliflozin and sotagliflozin (OR 1.39, 95% CI 0.68–2.78).
Conclusions
In patients with established heart failure, there was no significant difference of the major efficacy outcomes among SGLT2 inhibitor treatments; however, sotagliflozin may be associated with the lowest risk of the composite of cardiovascular death or hospitalization for heart failure, and dapagliflozin may be associated with the lowest risk of all-cause and cardiovascular mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China, 510317.
- Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China, 510515.
ORCID-Profile: Hai-Bin Chen
Zitieren
APA
Chen, H. B., Yang, Y. L., Meng, R. S., & Liu, X. W. (2023). Indirect Comparison of SGLT2 Inhibitors in Patients with Established Heart Failure: Evidence Based on Bayesian Methods. ESC Heart Failure. https://doi.org/10.1002/ehf2.14297
Vancouver
Chen HB, Yang YL, Meng RS, Liu XW. Indirect Comparison of SGLT2 Inhibitors in Patients with Established Heart Failure: Evidence Based on Bayesian Methods. ESC Heart Failure. 2023. doi:10.1002/ehf2.14297
BibTeX
@article{Chen2023,
author = {Chen, Hai-Bin and Yang, Yao-Lin and Meng, Rong-Sen and Liu, Xue-Wei},
title = {Indirect Comparison of SGLT2 Inhibitors in Patients with Established Heart Failure: Evidence Based on Bayesian Methods},
journal = {ESC Heart Failure},
year = {2023},
doi = {10.1002/ehf2.14297}
}
EUVIMED